Malaria is a mosquito-borne infectious disease that affects humans and other animals. Specifically, malaria caused Symptoms usually including fever, fatigue, vomiting and headache. Besides, malaria is due to the single-celled microorganisms of the Plasmodium group. The disease is most commonly transmitted by infected female Anopheles mosquitoes. Moreover, malaria caused by Plasmodium falciparum is a global catastrophic disease. Signs and symptoms of malaria usually begin 8-25 days after infection, but may occur later in patients who use antimalarial drugs as a preventive measure. Furthermore, antimalarials are an antiparasitic chemical, usually from natural sources, which can treat or prevent malaria. Widespread Plasmodium falciparum is dependent on many antimalarial drugs, such as artemisinin. New and effective antimalarial drugs need to be developed. SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent.
SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent.
How does SJ000025081 work on the target? Let’s study it together. In the beginning, SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent. Meanwhile, SJ000025081 results in an obvious suppression of the parasitemia in a murine malaria model infected with P. yoelii.
In the second place, SJ000025081 by intraperitoneal injection exhibits a good PK profile with 25 mg/kg of a single dose. Nonetheless, the Cmax, Cmax/Dose, Tmax and AUC values are 0.224 µg/ml, 0.0113 µg/ml per mg/ml, 1.0 h and 0.224 µg.h/ml, respectively. SJ000025081 by intraperitoneal injection exhibits an antimalarial activity in a dose-dependent manner with 5-100 mg/kg twice daily for 3 days. Particularly, SJ000025081 displays efficacy in a murine malaria model infected with P. yoelii. SJ000025081 can result in a 90% suppression of the parasitemia.
All in all, SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent.